Literature DB >> 22738309

Clinical experience with oral versus intravenous vitamin K for warfarin reversal.

Robert Meehan1, Maria Tavares, Joseph Sweeney.   

Abstract

BACKGROUND: Reversal of warfarin with plasma accounts for a large amount of fresh-frozen plasma transfused in the United States. The use of vitamin K is an alternate strategy. STUDY DESIGN AND METHODS: Records of vitamin K prescriptions for warfarin reversal were examined and recipients identified where data were available on dosage, route of administration (oral [PO] and intravenous [IV]) and the availability of both pre- and postadministration international normalized ratio(s) (INRs).
RESULTS: A total of 135 administration events were evaluated: 81 PO and 54 IV. The median (range) preadministration INRs were 5.8 (1.9-16.5) versus 5.0 (1.4-16.5; p=0.61) and the median (range) for the postadministration INRs were 2.4 (1.0-10.4) and 2.1 (1.2-8.2; p<0.01) for the PO and IV routes, respectively. The median (range) doses were 2.5(1-10) and 2.0(1-10) mg for PO and IV, respectively (p<0.01). A total of 44% of the IV vitamin K group achieved an INR of 2 or less within 12 hours versus 14% for the PO route (p<0.01). In multilinear regression the preadministration INR (r=0.14, p<0.01) and time after administration (r=-0.05, p<0.01) were independent variables influencing the postadministration INR but the dose administered (r=0.09, p=0.07) was not.
CONCLUSION: Vitamin K needs to be given IV if urgent partial correction (<12 hr) of warfarin is required. No influence of dose administered in the range 1 to 10 mg on the postadministration INR was observed.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22738309     DOI: 10.1111/j.1537-2995.2012.03755.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Perioperative management of antithrombotic and antiplatelet therapy.

Authors:  Arthur W Bracey
Journal:  Tex Heart Inst J       Date:  2015-06-01

Review 2.  Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety.

Authors:  Steven Deitelzweig
Journal:  Ochsner J       Date:  2013

Review 3.  Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.

Authors:  Kamrouz Ghadimi; Jerrold H Levy; Ian J Welsby
Journal:  Anesth Analg       Date:  2016-05       Impact factor: 5.108

4.  "Early Trigger" Intravenous Vitamin K: Optimizing Target-Driven Care in Warfarinised Patients With Hip Fracture.

Authors:  Marina Diament; Kirsty MacLeod; Jonathan O'Hare; Anne Tate; Will Eardley
Journal:  Geriatr Orthop Surg Rehabil       Date:  2015-12

Review 5.  Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.

Authors:  Lisa M Baumann Kreuziger; Joseph C Keenan; Colleen T Morton; David J Dries
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

Review 6.  Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.

Authors:  Ali Zalpour; Thein Hlaing Oo
Journal:  Drug Des Devel Ther       Date:  2014-11-05       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.